Nanda Balasubramanian discusses the pivotal role of bioanalysis in advancing pharmaceutical science. He shares key innovations in bioanalytical techniques to reduce the burden on patients and improve turnaround times of assays. Balasubramanian also addresses the unique challenges of bioanalysis for therapeutic modalities like mRNA therapeutics, CAR-T, and small molecules. Plus, he discusses the need to adapt processes by incorporating lessons learned in the context of new modality drug development.